Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Baghaei, P. Tabarsi, M. Marjani, D. Mansouri, M. R. Masjedi (Tehran, Islamic Republic Of Iran). Adverse effects of MDR-TB treatment with a standardized regimen: A report from Iran. Eur Respir J 2010; 36: Suppl. 54, 3139

Member's Comments

No comment yet.

Related content which might interest you: Adverse effects of treatment in HIV-associated tuberculosis patients in Iran Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 A prospective study of prevalence of adverse drug reactions to the short course anti-tuberculosis regimen in Korea Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007 Adverse effects in patients receiving therapy for multi-drug resistant tuberculosis in Latvia Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012 Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012 Adverse effects analysis results during anti-TB treatment among hemodialysis patients Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Spectrum of adverse drug reactions during MDR TB treatment Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report Source: Eur Respir J, 54 (6) 1901522; 10.1183/13993003.01522-2019 Year: 2019 Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 Adverse effects of anti-tuberculosis drugs in hemodialysis patients Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Short 12-month regimen with intravenouse linezolid for MDR-TB:  treatment outcomes and first follow up results. Source: International Congress 2018 – New developments in tuberculosis Year: 2018 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Adverse effects of moxifloxacin during tuberculosis treatment Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Adverse effects of chemotherapy in patients with multidrug-resistant tuberculosis with alcohol abuse and without one Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018